In vitro comparison of myometrial contractility induced by aglepristone-oxytocin and aglepristone-PGF2alpha combinations at different stages of the estrus cycle in the bitch.
The aim of this in vitro study was to compare the uterokinetic activity of oxytocin and dinoprost, the natural PGF2α, with or without aglepristone, in canine myometrial fibers. Thirty-three bitches were allocated into one of four groups, depending on their estrous stage and whether or not they had received a treatment with aglepristone (metestrus aglepristone, n = 5; metestrus without treatment, n = 9; anestrus aglepristone, n = 9; anestrus without treatment, n = 10). After hysterectomy, longitudinal and circular uterine strips were mounted in organ baths. Oxytocin or PGF2α (10 nmol/l to 10 micromol/l) were applied non-cumulatively. A linear mixed effects models theory was used to compare the fiber effect, the aglepristone effect, and the treatment effect, from the area under the curves calculated from the contractile effect/concentration curves for each drug. Oxytocin and PGF2α induced concentration-dependent myometrial contractions in longitudinal (LF) and circular myometrial fibers (CF), indicating the presence of functional contractile oxytocin- and PGF2α-receptors in metestrus and anestrus. The contractile response to oxytocin was greater in LF than in CF in all of the groups; the response to PGF2α was greater in LF than in CF in non-treated bitches in anestrus and in treated bitches in metestrus. These results suggest that there is a difference in sensitivity or a heterogeneous distribution of oxytocin and PGF2α-receptors in the myometrial layers, which is independent of hormonal impregnation. The contractile response to oxytocin and PGF2α was significantly increased after aglepristone treatment in LF during metestrus, suggesting that the progesterone withdrawal induced by aglepristone has a role to play. The longitudinal myometrial layer also appeared to be the target for the two drugs at this stage. This study provides new information about canine uterine contractile activity, notably the differing behavior of myometrial CF and LF; in vivo studies are required to test the use of a combination of aglepristone and oxytocin in the treatment of canine pyometra.
Gogny
A
A
Laboratory of Biotechnology and Pathology of Reproduction, Nantes-Atlantic National College of Veterinary Medicine, Food Science and Engineering-ONIRIS, F-44307 Nantes, France. anne.gogny@oniris-nantes.fr
Mallem
Y
Y
Destrumelle
S
S
Thorin
C
C
Desfontis
J-C
JC
Gogny
M
M
Fiéni
F
F
D000818:Animals; D015237:Dinoprost / Q000494:pharmacology*; D004285:Dogs / Q000502:physiology*; D004963:Estrenes / Q000494:pharmacology*; D004971:Estrus / Q000502:physiology*; D005260:Female; D066298:In Vitro Techniques; D009215:Myometrium / Q000187:drug effects / Q000502:physiology; D010120:Oxytocics / Q000494:pharmacology*; D010121:Oxytocin / Q000494:pharmacology*; D011374:Progesterone / Q000097:blood; D014590:Uterine Contraction / Q000187:drug effects*
D004963:Estrenes; D010120:Oxytocics; C419063:aglepristone; D011374:Progesterone; D010121:Oxytocin; D015237:Dinoprost